Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
The Institute of Bioengineering and Nanotechnology of A*STAR has reported superior results using new green tea-based nanocarriers to kill liver cancer cells, compared to existing drug delivery systems.
Several studies being presented at the American College of Cardiology's 67th Annual Scientific Session demonstrate how the computer science technique known as machine learning can be used to accurately predict clinical outcomes in patients with known or potential heart problems.
Patients who were treated for breast cancer or lymphoma are more than three times at risk for developing congestive heart failure, compared with patients who did not have cancer. Congestive heart failure is when the heart muscle does not pump blood as well as it should.
Breast cancer patients may be at an increased risk of cardiovascular diseases including heart failure and may benefit from a treatment approach that weighs the benefits of specific therapies against potential damage to the heart, according to a new scientific statement from the American Heart Association published in its journal Circulation.
Delivering drugs specifically to cancer cells is one approach researchers are taking to minimize treatment side effects. Stem cells, bacteria and other carriers have been tested as tiny delivery vehicles.
A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.
Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 (IGPR-1) which was recently identified in the same laboratory as a cell adhesion molecule.
Researchers from Case Western Reserve University School of Medicine in collaboration with researchers from Dartmouth Geisel School of Medicine and RWTH Aachen University have adapted virus particles- that normally infect potatoes- to serve as cancer drug delivery devices for mice.
Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. The blood cancer can affect both children and adults.
A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.
Men seem to have worse chemotherapy-induced cardiomyopathy than women despite receiving similar cancer treatments, according to research presented today at EuroCMR 2017.
For the first time, WSU researchers have demonstrated a way to deliver a drug to a tumor by attaching it to a blood cell. The innovation could let doctors target tumors with anticancer drugs that might otherwise damage healthy tissues.
Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
The third annual Cardiovascular Tissue Engineering Symposium met at the University of Alabama at Birmingham last month, a gathering of noted physicians and scientists who share the goal of creating new tissues and new knowledge that can prevent or repair heart disease and heart attacks.
A short-term fast appears to counteract increases in blood sugar caused by common cancer drugs and protect healthy cells in mice from becoming too vulnerable to chemotherapy, according to new research from the University of Southern California.
Chemists at the University of Alabama at Birmingham have designed triple-threat cancer-fighting polymer capsules that bring the promise of guided drug delivery closer to preclinical testing.
A team of researchers led by Alex Toker of the Ludwig Center at Harvard has discovered a metabolic weakness in triple-negative breast cancer cells that may be exploited to quell their resistance to chemotherapy.
Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project "Hide and Seek with Cancer Drugs" in which he is working to improve the drugs used in cancer treatment
The time of day that breast cancer chemotherapy drugs are given affects the amount of damaging inflammation in the body, a new study in mice suggests.
Standard chemotherapy is a blunt force instrument against cancer - and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body.